Other preclinical investigations demonstrated positive benefits of SF on AD by attenuating Aβ oligomers-mediated reduction of phagocytic activity (5 μM for 24 h) (72), reducing streptozotocin-induced cognitive deficits (141 or 282 μmol/kg/day for 6 weeks) (73), decreasing neuroinflammation and inhibiting tau phosphorylation (1 or 2 μM for 1 h and stimulated with LPS for 23 h) (73), and reducing Aβ production (226 μmol/kg three times a week for 4 weeks) (74) in in vivo and in vitro AD models. The gene discussed is MAPT; the disease is Alzheimer disease.